Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Poster presentation

EGFR unusual mutation status in lung adenocarcinomas

Ana Alarcão12*, Vitor Sousa1234, Patrícia Couceiro12, Maria Silva123, Maria J d’Aguiar1, Lia Teixeira1 and Lina Carvalho1234

Author Affiliations

1 Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

2 Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal

3 Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

4 Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, Portugal

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P61  doi:10.1186/1753-6561-4-S2-S61

The electronic version of this article is the complete one and can be found online at:

Published:24 September 2010

© 2010 Alarcão et al; licensee BioMed Central Ltd.

Poster presentation

Lung cancer is the most common cause of cancer deaths in both men and women. Adenocarcinoma represents about 28% of the NSCLC cases in men and 42% in women. EGFR is a member of the ERBB family of tyrosine kinases (TK). EGFR mutations are more frequently observed in female, non-smokers, East-Asian and in patients with adenocarcinomas, and predict response to TK Inhibitors (TKIs).

Sections of adenocarcinomas of the lung, formalin-fixed paraffin-embedded tissues (FFPE), were selected to analyze mutations in EGFR exons 19 and 21 by DNA extraction for polymerase chain reaction (PCR). Exon 19 was studied by fragment analysis and exon 21 was studied by direct sequencing. The analysis of FISH results was done by Cappuzzo’s score to EGFR gene. Determination of EGFR protein expression was done by immunohistochemistry (IHC) (Zymed Laboratories).

The author’s present two cases of lung adenocarcinoma that harbours coexisting EGFR exon 19 and 21 mutations and one case of EGFR multiple in frame-deletions. The patients were female (n = 3), with mixed type adenocarcinoma overexpressing EGFR by IHC.

Most reports demonstrate one EGFR mutation per adenocarcinoma. We demonstrated that a single adenocarcinoma can harbour more than one EGFR activating mutations.